RxDoctor Payments Data

Lance Radbill, DO

Obstetrics & Gynecology · Birmingham, ALNPI 1740244383

Payments from drug & device makers

$3,910in general payments, 2019–2025

Across 195 payments — averaging $20.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Allegis Pharmaceuticals, LLC$790
  • AbbVie$654
  • Astellas Pharma US Inc$440
  • Sumitomo Pharma America, Inc.$297
  • Amgen$142
  • Hologic Sales And Service, LLC$124
  • plus $1K from 36 others

What the payments were for

  • Food & beverage$3,896100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,910 in reported general payments places this provider in the 75th percentile of 537 obstetrics & gynecology providers in Alabama.

See all obstetrics & gynecology providers in Alabama

Medicare billing

Part B allowed, 2024
$17,560
Medicare patients
111
Services billed
300

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron13$14,796
PremarinEstrogens, Conjugated27$10,725
Estradiol226$8,932
GemtesaVibegron14$6,524
Estradiol (Twice Weekly)Estradiol61$4,756
Solifenacin Succinate72$3,284
DottiEstradiol24$2,475
Clobetasol Propionate35$2,074
ProgesteroneProgesterone, Micronized34$1,356
ValacyclovirValacyclovir Hcl12$989
Raloxifene Hcl12$961
Fluoxetine Hcl28$453
Medroxyprogesterone Acetate19$236
Citalopram HbrCitalopram Hydrobromide20$152
Zolpidem Tartrate12$19

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$440$14,79613 claims
PfizerPremarin$113$10,72527 claims
Sumitomo Pharma America, Inc.Gemtesa$297$6,52414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 537 obstetrics & gynecology providers in Alabama.

Other obstetrics & gynecology in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →